R L Dunbar

Summary

Affiliation: University of Pennsylvania
Country: USA

Publications

  1. ncbi request reprint Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?
    R L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA, USA
    Minerva Endocrinol 29:89-111. 2004
  2. ncbi request reprint The unsung perils of peripheral arterial disease: a malady in search of a patient
    Richard L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Prev Cardiol 8:108-13; quiz 114-5. 2005
  3. ncbi request reprint Demystifying triglycerides: a practical approach for the clinician
    Richard L Dunbar
    Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA
    Cleve Clin J Med 72:661-6, 670-2, 674-5 passim. 2005
  4. pmc Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
  5. pmc Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009

Detail Information

Publications5

  1. ncbi request reprint Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera?
    R L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA, USA
    Minerva Endocrinol 29:89-111. 2004
    ..We review the limited data available regarding metabolic syndrome, with a focus on expert opinion gleaned from clinical guidelines, and offer advice to the clinician from our own experience with this population...
  2. ncbi request reprint The unsung perils of peripheral arterial disease: a malady in search of a patient
    Richard L Dunbar
    University of Pennsylvania Medical School, Philadelphia, PA 19104, USA
    Prev Cardiol 8:108-13; quiz 114-5. 2005
    ..This article will review the relationship between PAD and other vascular disease, emphasizing the role of PAD in prevention efforts...
  3. ncbi request reprint Demystifying triglycerides: a practical approach for the clinician
    Richard L Dunbar
    Cardiovascular Risk Intervention Program, University of Pennsylvania School of Medicine, Philadelphia, USA
    Cleve Clin J Med 72:661-6, 670-2, 674-5 passim. 2005
    ..The third report of the National Cholesterol Education Program's Adult Treatment Panel (ATP-III) provides a much-needed strategy for managing patients with high triglycerides, based on the best available evidence...
  4. pmc Seeing red: flushing out instigators of niacin-associated skin toxicity
    Richard L Dunbar
    Department of Medicine, Division of Experimental Therapeutics, Institute for Translational Medicine and Therapeutics, Pennsylvania 19104, USA
    J Clin Invest 120:2651-5. 2010
    ..These efforts bring us one step closer to solving a key limitation of an important cardioprotective drug and reveal that the skin response to niacin is much more complicated than previously thought...
  5. pmc Potent and selective PPAR-alpha agonist LY518674 upregulates both ApoA-I production and catabolism in human subjects with the metabolic syndrome
    John S Millar
    Departments of Pharmacology, University of Pennsylvania, 652 BRB II III, 421 Curie Blvd, Philadelphia, PA 19104, USA
    Arterioscler Thromb Vasc Biol 29:140-6. 2009
    ..We sought to determine the effect of a potent and highly specific PPAR-alpha agonist, LY518674, on apoA-I, apoA-II, and apoB-100 kinetics in humans with metabolic syndrome and low levels of HDL cholesterol (C)...